Literature DB >> 12031332

Nicotinanilides as inhibitors of neutrophil chemotaxis.

Neil S Cutshall1, Kristin A Kucera, Rocky Ursino, John Latham, Nathan C Ihle.   

Abstract

A series of 4-fluoronicotinanilides was synthesized and shown to be novel, potent, and selective inhibitors against GRO-alpha-driven human neutrophil chemotaxis. Compounds of this class may be useful for the treatment of inflammatory, autoimmune, and allergic disorders.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12031332     DOI： 10.1016/s0960-894x(02)00188-9

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  6 in total

1.  Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism.

Authors:  Dean Y Maeda; Mark T Quinn; Igor A Schepetkin; Liliya N Kirpotina; John A Zebala
Journal:  J Pharmacol Exp Ther       Date:  2009-09-24       Impact factor: 4.030

2.  3,5-Bis(ethoxy-carbon-yl)-2,6-dimethyl-1,4-dihydro-pyridine-4-carboxylic acid.

Authors:  De-Hong Wu; Ling Hu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-07-04

3.  Diethyl 2,6-dimethyl-4-phenyl-1,4-dihydro-pyridine-3,5-dicarboxyl-ate.

Authors:  Ming-Sheng Bai; Yan-Yun Chen; Dong-Ling Niu; Li Peng
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-03-19

4.  IL-8 signaling does not mediate intra-amniotic LPS-induced inflammation and maturation in preterm fetal lamb lung.

Authors:  Suhas G Kallapur; Timothy J M Moss; Richard L Auten; Ilias Nitsos; J Jane Pillow; Boris W Kramer; Dean Y Maeda; John P Newnham; Machiko Ikegami; Alan H Jobe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-07-02       Impact factor: 5.464

Review 5.  Therapy for chronic obstructive pulmonary disease in the 21st century.

Authors:  Louise E Donnelly; Duncan F Rogers
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.

Authors:  Dean Y Maeda; Angela M Peck; Aaron D Schuler; Mark T Quinn; Liliya N Kirpotina; Winston N Wicomb; Guo-Huang Fan; John A Zebala
Journal:  J Med Chem       Date:  2014-10-08       Impact factor: 7.446
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.